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Aim: A network meta-analysis using randomized controlled trial data compared psoriatic arthritis (PsA)
outcomes (American College of Rheumatology [ACR], Psoriasis Area Severity Index [PASI] and Psori-
atic Arthritis Response Criteria [PsARC] response rates) at 12–16 weeks for secukinumab, adalimumab,
apremilast, certolizumab, etanercept, golimumab, infliximab and ustekinumab. Patients & methods: Tri-
als were identified by systematic review. Separate networkswere developed for the full-study populations,
biologic-naive patients and biologic-experienced patients. Results: In the full populations, secukinumab,
adalimumab, golimumab and infliximab demonstrated the highest ACR response rates. Secukinumab and
infliximab demonstrated the highest PASI response rates, and infliximab and etanercept demonstrated
the highest PsARC response rates. Conclusion: In the full populations, secukinumab demonstrated good
efficacy across all outcomes. All treatments for active PsA included in this comprehensive network meta-
analysis demonstrated superiority to placebo.
First draft submitted: 19 July 2018; Accepted for publication: 3 September 2018; Published online:
19 September 2018
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Psoriatic arthritis (PsA) is characterized by chronic inflammation, with musculoskeletal and dermatological issues,
and other co-morbidities [1]. The pain, stiffness and swelling associated with PsA are often accompanied by structural
damage to the joints, impairing patients’ physical functioning and often resulting in severe disability [2]. The aim of
treatment is to achieve sustained, low disease activity or remission, maximizing quality of life in the long term [2].
Current immune-modifying therapies, including biologics and targeted synthetic disease-modifying anti-
rheumatic drugs (tsDMARDs), are recommended by several international guidelines for use if conventional
DMARDs (cDMARDs), employed as first-line therapies, are not successful [3,4]. The earliest biologic therapies
approved for the treatment of PsA targeted TNF. At present, five such agents (adalimumab, certolizumab, etan-
ercept, golimumab and infliximab) have been approved, with biosimilars also now widely available. Two agents,
J. Comp. Eﬀ. Res. (Epub ahead of print) ISSN 2042-630510.2217/cer-2018-0075 C© 2018 Steffen M Jugl
Research Article McInnes, Nash, Ritchlin et al.
secukinumab and ustekinumab, which have been approved more recently, are directed against cytokines that are
implicated in the pathophysiology of PsA and related disorders by genetic and tissue-based pathogenesis inves-
tigations [5]. Secukinumab is a fully human monoclonal antibody targeting IL-17A, which is involved in the
pathogenesis of PsA as well as other autoimmune diseases in the spondyloarthritis family [6,7]. Ustekinumab is a
fully human monoclonal antibody directed against the p40 subunit of IL-12 and IL-23. Like IL-17, IL-23 has been
implicated in the pathogenesis of autoimmune diseases, including PsA [8]. In addition, the tsDMARD apremilast, a
small-molecule inhibitor that modulates inflammatory cytokine production via inhibition of phosphodiesterase-4,
has also been approved recently for the treatment of PsA.
The optimal treatment pathway to achieve the objectives set out in guidelines merits further investigation. In
particular, there is an increasing need for comparative evidence on the efficacy of the foregoing treatments. Three
randomized controlled trials (RCTs) have reported direct comparisons between biologic therapies employed in
the treatment of patients with psoriasis: the CLEAR trial [9], which compared secukinumab and ustekinumab
(NCT02074982); the FIXTURE trial [10] between secukinumab and etanercept (NCT01358578); and the AC-
CEPT study between ustekinumab and etanercept (NCT00454584) [11]. The CLEAR and FIXTURE trials
included subpopulation analyses for patients with both psoriasis and PsA; however, these trials were conducted to
compare the effects of these treatments in patients with psoriasis, and therefore had a focus on skin outcomes rather
than articular inflammation. In the CLEAR trial, among patients with psoriasis and PsA, a significantly greater
proportion receiving secukinumab 300 mg achieved a Psoriasis Area Severity Index 90 (PASI90) response (i.e., an
improvement of at least 90% in PASI score) as early as week 8 compared with patients who received ustekinumab.
This significant difference between treatment groups was sustained from week 16 onward: approximately 80%
of patients receiving secukinumab achieved a PASI90 response at all time points through to week 52 [9]. In the
FIXTURE trial, patients with psoriasis and PsA receiving secukinumab 300 mg were significantly more likely to
achieve a PASI75 response at week 12 compared with patients receiving etanercept [10]. Comparatively higher rates
of PASI75 and PASI90 response for patients receiving secukinumab 300 mg were sustained until week 52. The
efficacy of biologics and tsDMARDs in patients with PsA has been demonstrated across many placebo-controlled
trials; however, to our knowledge, only two trials directly comparing treatments for PsA and powered for superiority
have been initiated and are currently ongoing. EXCEED 1 is intended to compare the efficacy of secukinumab and
adalimumab [12], and SPIRIT-H2H will compare ixekizumab and adalimumab [13]. Unlike previous head-to-head
trials, both of these studies will examine articular outcomes as well as skin outcomes. Currently, in the absence
of findings from head-to-head trials, adjusted indirect comparisons provide the best available evidence allowing
differentiation between treatments for PsA.
Network meta-analysis (NMA) is an extension of traditional pairwise meta-analysis. NMA compares outcomes
across a number of treatments when relevant trials can be ‘connected’ into a network directly, or indirectly by use of
common comparators, or both. NMA is increasingly used and accepted in comparative effectiveness research and
healthcare decision-making [14,15]. Several analyses have used NMA to compare PsA treatments [16–20]; however, not
all of them have compared the full range of approved therapies. Here, we have developed networks to compare all
biologics and tsDMARDs for PsA approved at the time at which our study was conducted, with a focus on pairwise
comparisons against secukinumab. The current study has been carried out in line with established standards [21,22]
to meet health technology assessment requirements, and provides further comparative effectiveness data for PsA
therapies.
Patients & methods
Systematic literature review
A systematic review of literature published up to 6 November 2015 identified trials of approved biologic therapies
and tsDMARDs for patients with active PsA who had experienced an inadequate response to cDMARDs. The
therapies of interest were adalimumab, certolizumab, etanercept, golimumab, infliximab, secukinumab and ustek-
inumab, and the non-biologic therapy apremilast. Relevant efficacy outcomes extracted from the trials identified
included American College of Rheumatology 20 (ACR20), ACR50 and ACR70 responses (indicating at least a
20/50/70% improvement in the core set of ACR measures for assessing arthritis); PASI50, PASI75 and PASI90
responses (indicating at least a 50/75/90% reduction in PASI score); and Psoriatic Arthritis Response Criteria
(PsARC) responses. Further details can be found in Supplementary Methods; trial inclusion criteria are given in
Supplementary Table 1.
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Treatment networks
Three treatment networks were developed: one for ACR responses, one for PASI responses and one for PsARC
responses. Principal networks were developed for the full study populations (termed the ‘mixed’ populations),
which included all patients, regardless of whether they had received previous biologic therapy. Networks were
also developed for trials reporting data from ‘biologic-naive’ patients at study entry as a separate subpopulation. A
network was developed for ‘biologic-experienced’ patients for ACR responses only, as there was insufficient evidence
reported for the other outcomes. Data used in the networks were those collected at time points up to week 16, the
point at which many patients receiving placebo switched to active treatment, particularly in the major trials for
apremilast, certolizumab, golimumab, infliximab, secukinumab and ustekinumab.
NMA & statistical methodology
ACR and PASI responses were modeled using a Bayesian NMA with probit link function and conditional multino-
mial likelihood [21]. This approach can be adopted in cases in which continuous data (e.g., PASI score) are interpreted
using a prespecified cut-off point to generate binomial data for analyses (e.g., response or non-response). For PsARC,
a dichotomous composite measure developed specifically for use in PsA, a generalized linear model with logit link
function and binomial likelihood, was used. Where feasible, for each treatment network, both random-effect and
fixed-effect models were conducted. Models with baseline adjustments for placebo response were conducted where
needed and feasible. Several factors were examined in order to assess the fit of each model, including the deviance
information criterion (see Supplementary Methods).
The output of the Bayesian NMAwas a posterior distribution of relative treatment effects, represented as median
relative risks with 95% credible intervals, which were constructed from the 2.5th and 97.5th percentiles of the
posterior distribution, and can be interpreted in a similar way to CIs. There was considered to be statistical evidence
of superiority for a treatment over a given comparator when the relative risk of an ACR, PASI or PsARC response
was >1 at both upper and lower 95% credible interval. This can be interpreted as analogous to testing a two-sided
p-value at the 5% threshold.
Sensitivity analyses
When feasible, sensitivity analyses were used to examine the impact of including or excluding certain studies in
each network. One sensitivity analysis examined the impact of adding adalimumab and placebo data from SPIRIT-
P1 [23,24]. This study was excluded from the original network because it is a trial including ixekizumab, which was
not approved at the time the analyses were carried out. Three different iterations of the analysis by time point were
also performed:
• Inclusion of all trials that reported at 12–16 weeks
• Restriction of network to only those trials that reported at 12 weeks
• Restriction of network to only those trials that reported at 16 weeks
Results
Study selection
Following full-text screening of publications identified by systematic review, 20 trials were selected for potential
inclusion in the NMA. Of these, 17 included ACR20/50/70 responses, 19 included PASI50/75/90 responses
and 13 included PsARC responses (Table 1). A feasibility assessment determined the degree of heterogeneity across
the different trials, examined the quality of the data and established that the selected trials could be used to
develop a network. Subsequently, the SPIRIT-P1 trial [23,24] was identified separately for potential inclusion. This
placebo-controlled study investigating the efficacy of ixekizumab contains adalimumab as an active control arm.
Details of included studies’ designs and populations are given in Tables 1 & 2. For adalimumab, golimumab and
infliximab, populations were entirely biologic-naive, whereas data for the remainder of the therapies came from
mixed populations in which some patients were biologic-experienced. In trials that reported data from biologic-
experienced populations, disparities in inclusion criteria meant that patients receiving certain agents might have
experienced several previous anti-TNF therapy failures, whereas other populations were permitted to have received
only one previous anti-TNF therapy. There were also differences between trials in terms of the methods used to
future science group 10.2217/cer-2018-0075
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Table 1. Study details for trials included in sensitivity analyses.
Trial name [Ref.] Relevant treatments
(number of patients
randomized)
Primary endpoint(s) Use in ACR NMA
(reason for exclusion)
Use in PASI
NMA (reason for
exclusion)
Use in PsARC
NMA (reason for
exclusion)
Imputation
method
Population
composition†
ADEPT [25] Adalimumab 40 mg
(153)
Placebo (162)
ACR20 response at 12
weeks
Modified Sharp score
change from baseline
at 24 weeks
Yes Yes Yes NRI Biologic-naive
CLEAR [9] Secukinumab 300 mg
(69)
Ustekinumab 45 mg
(54)
PASI90 response at
16 weeks
No (ACR data not
collected)
Yes No (PsARC data
not reported)
NRI Mixed
ERASURE [10] Secukinumab 150 mg
(46)
Secukinumab 300 mg
(57)
Placebo (68)
PASI75 response at
12 weeks
IGA Mod 2011 at
12 weeks
No (ACR data not
collected)
Yes No (PsARC data
not reported)
NRI Mixed
FIXTURE [10] Etanercept 50 mg BIW
(44)
Secukinumab 150 mg
(49)
Secukinumab 300 mg
(50)
Placebo (49)
PASI75 response at
12 weeks
IGA Mod 2011 at
12 weeks
No (ACR data not
collected)
Yes No (PsARC data
not reported)
NRI Mixed
FUTURE 1 [26] Secukinumab 150 mg
(202)
Secukinumab 300 mg
(202)
Placebo (202)
ACR20 response at
24 weeks
No (excluded owing to
intravenous loading
doses, which do not
reflect approved
posology)
No (excluded
owing to
intravenous
loading doses,
which do not
reflect approved
posology)
No (excluded
owing to
intravenous
loading doses,
which do not
reflect approved
posology)
NRI Mixed
FUTURE 2 [27] Secukinumab 150 mg
(100)
Secukinumab 300 mg
(100)
Placebo (98)
ACR20 response at
24 weeks
Yes Yes Yes NRI Mixed
Genovese et
al. [28]
Adalimumab 40 mg
(51)
Placebo (51)
ACR20 response at
12 weeks
No (excluded owing to
lack of 16-week data)
No (no PASI data
reported)
Yes NRI Biologic-naive
GO-REVEAL [29] Golimumab 50 mg
(146)
Golimumab 100 mg
(146)
Placebo (113)
ACR20 response at
14 weeks
Yes Yes Yes LOCF Biologic-naive
IMPACT [30] Infliximab 5 mg/kg (52)
Placebo (52)
ACR20 response at
14 weeks
Yes Yes Yes Unclear Biologic-naive
IMPACT2 [31] Infliximab 5 mg/kg
(100)
Placebo (100)
ACR20 response at
14 weeks
Yes Yes Yes NRI/LOCF Biologic-naive
Mease et al. [32] Etanercept 25 mg BIW
(30)
Placebo (30)
PsARC response at
12 weeks
No (excluded owing to
lack of 16-week data)
Yes Yes LOCF Not reported
Mease et al. [33] Etanercept 25 mg BIW
(101)
Placebo (104)
ACR20 response at
12 weeks
No (excluded owing to
lack of 16-week data)
No Yes LOCF Not reported
PALACE 1 [34] Apremilast 20 mg (168)
Apremilast 30 mg (168)
Placebo (168)
ACR20 response at
16 weeks
Yes Yes Yes NRI Mixed
PALACE
2 [35,36]
Apremilast 20 mg (163)
Apremilast 30 mg (162)
Placebo (159)
ACR20 response at
16 weeks
Yes Yes Yes Unclear Mixed
†Study populations were either mixed (including both biologic-naive and biologic-experienced patients) or biologic-naive.
‡With a 400 mg loading dose.
ACR20: At least a 20% improvement in the core set of American College of Rheumatology measures for assessing arthritis; BIW: Twice per week; IGA Mod 2011: Investigator’s Global
Assessment (modified in 2011); LOCF: Last observation carried forward; NMA: Network meta-analysis; NRI: Non-responder imputation; PASI75/90: At least a 75/90% reduction in
Psoriasis Area Severity Index score; PsARC: Psoriatic Arthritis Response Criteria; QW: Once a week.
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Table 1. Study details for trials included in sensitivity analyses (cont.).
Trial name [Ref.] Relevant treatments
(number of patients
randomized)
Primary endpoint(s) Use in ACR NMA
(reason for exclusion)
Use in PASI
NMA (reason for
exclusion)
Use in PsARC
NMA (reason for
exclusion)
Imputation
method
Population
composition†
PALACE 3 [37] Apremilast 20 mg (169)
Apremilast 30 mg (167)
Placebo (169)
ACR20 response at
16 weeks
Yes Yes Yes NRI Mixed
PRESTA [38] Etanercept 50 mg BIW
(379)
Etanercept 50 mg QW
(373)
Proportion of patients
achieving ‘clear’ or
‘almost clear’ on the
physician’s global
assessment of psoriasis
at 12 weeks
No (reported ACR
response data, but
could not be linked to
ACR treatment
network via placebo or
an active comparator)
Yes No (PsARC data
not reported)
LOCF Biologic-naive
PSUMMIT1 [39] Ustekinumab 45 mg
(205)
Ustekinumab 90 mg
(204)
Placebo (206)
ACR20 response at
24 weeks
Yes No No (PsARC data
not reported)
LOCF Biologic-naive
PSUMMIT2 [40] Ustekinumab 45 mg
(103)
Ustekinumab 90 mg
(105)
Placebo (104)
ACR20 response at
24 weeks
Yes No No (PsARC data
not reported)
LOCF Mixed
RAPID-PsA [41] Certolizumab 200 mg‡
(138)
Certolizumab 400 mg‡
(135)
Placebo (136)
ACR20 response at
12 weeks
Modified total Sharp
score change from
baseline at 24 weeks
Yes Yes Yes NRI Mixed
Schett et al. [42] Apremilast 20 mg (69)
Apremilast 40 mg (67)
Placebo (68)
ACR20 response at
12 weeks
No (excluded owing to
lack of 16-week data)
No (no PASI data
reported)
Yes LOCF Mixed
SPIRIT-P1 [23,24] Adalimumab 40 mg
(101)
Placebo (106)
ACR20 response at
24 weeks
No (excluded following
sensitivity analysis)
Yes No NRI Biologic-naive
†Study populations were either mixed (including both biologic-naive and biologic-experienced patients) or biologic-naive.
‡With a 400 mg loading dose.
ACR20: At least a 20% improvement in the core set of American College of Rheumatology measures for assessing arthritis; BIW: Twice per week; IGA Mod 2011: Investigator’s Global
Assessment (modified in 2011); LOCF: Last observation carried forward; NMA: Network meta-analysis; NRI: Non-responder imputation; PASI75/90: At least a 75/90% reduction in
Psoriasis Area Severity Index score; PsARC: Psoriatic Arthritis Response Criteria; QW: Once a week.
adjust for missing data; some used nonresponder imputation (NRI), whereas others employed the less conservative
last observation carried forward imputation approach.
Treatment networks
The treatment networks selected for each outcome in the mixed population are shown in Figure 1. For ACR
responses, networks were limited to studies reporting data at week 16, meaning that the studies of Genovese et
al. [28], Mease et al. [32,33] and Schett et al. [42] were excluded. SPIRIT-P1 [23,24] was not included. Thus, the final
network contained 11 studies. For PASI responses, the evidence base was smaller when networks were restricted
by time point. Therefore, available evidence was maximized by using data from 12–16-week time points, and
including data from SPIRIT-P1 [23,24]; the final network contained 15 trials. For PsARC responses, data from
12–16-week time points were used. The treatment network contained 13 trials. Networks for the biologic-naive
and biologic-experienced populations are shown in Supplementary Figures 1 & 2.
Model selection
Values for the deviance information criterion were similar across models for ACR and PASI scores, regardless of
adjustments for placebo response or other covariates. Thus, unadjusted models were selected for both networks. The
leverage plots assessing model fit indicated that a model adjusted for placebo response was the best fit for PsARC
responses in our study, and, consequently, this model was used for PsARC analyses in both mixed and biologic-naive
populations. This approach has been recommended previously to avoid the introduction of bias when using data
from studies in which placebo response improves over time [43]. For all mixed populations, random-effect models
were selected to address the potential heterogeneity across trials identified in the feasibility assessment. The relatively
future science group 10.2217/cer-2018-0075
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Table 2. Trial design details for studies including biologic-experienced patients.
Trial [Ref.] Relevant
treatments
Inclusion of
patients with
previous primary
treatment failure†
Inclusion of
patients with
previous secondary
treatment failure‡
Relevant inclusion criteria for
biologic-experienced patients
Relevant exclusion criteria for
biologic-experienced patients
CLEAR [9] Secukinumab
300 mg
Ustekinumab 45 mg
Study publication did not differentiate
between primary and secondary
treatment failure
Patients were eligible if their psoriasis had
been poorly controlled with biologic
therapy
Patients who had received
secukinumab, ustekinumab or
other biologic drugs targeting
IL-17A or IL-17RA were excluded
ERASURE [10] Secukinumab
150 mg
Secukinumab
300 mg
Placebo
Study publication did not differentiate
between primary and secondary
treatment failure
Patients who had received previous
biologic therapy were eligible; prestudy
washout periods were 6 months for
ustekinumab and 12 weeks for other
biologics or etanercept
NA
FIXTURE [10] Etanercept 50 mg
BIW
Secukinumab
150 mg
Secukinumab
300 mg
Placebo
– – Patients who had received previous
biologic therapy were eligible; prestudy
washout periods were 6 months for
ustekinumab and 12 weeks for other
biologics
Patients were not permitted to
have received etanercept
previously
FUTURE 2 [27] Secukinumab
150 mg
Secukinumab
300 mg
Placebo
Yes Yes Patients who had previously received ≤ 3
anti-TNF agents were eligible for inclusion
if they had not responded to treatment or
had discontinued treatment for safety or
tolerability reasons
Patients who had previously
received any biologic agent other
than anti-TNF agents were
excluded
PALACE 1 [34,44] Apremilast 20 mg
Apremilast 30 mg
Placebo
Yes Yes Patients who had previously received
biologics, including patients who had not
responded to biologic treatment, were
eligible for inclusion. TNF efficacy failures
were permitted in ≤10% of included
patients
Patients who had previously
experienced treatment failure with
3 agents for PsA (small molecules
and/or biologics) or 1 anti-TNF
were excluded
PALACE
2 [35,44]
Apremilast 20 mg
Apremilast 30 mg
Placebo
Yes Yes Patients were permitted to have received
biologics. TNF efficacy failures were
permitted in ≤10% of included patients.
Washout periods were 12 weeks for
adalimumab, certolizumab, etanercept,
golimumab or infliximab, and 24 weeks for
ustekinumab
Patients who had previously
experienced treatment failure with
3 agents for PsA (small molecules
and/or biologics) or 1 anti-TNF
were excluded
PALACE
3 [37,44]
Apremilast 20 mg
Apremilast 30 mg
Placebo
Yes Yes Patients were permitted to have received
biologics. TNF efficacy failures were
permitted in ≤10% of included patients
Patients who had previously
experienced treatment failure with
3 agents for PsA (small molecules
and/or biologics) or 1 anti-TNF
were excluded
PSUMMIT2 [40] Ustekinumab 45 mg
Ustekinumab 90 mg
Placebo
Yes Yes The protocol specified that 150–180
patients out of a total of 300 must have
previously received anti-TNF agents,
defined as adalimumab, certolizumab,
etanercept or golimumab for at least
8 weeks, or infliximab for at least 14 weeks,
or proven inability to tolerate anti-TNF
therapy for 8–14 weeks
Patients who had received
anti-IL-12/23 agents were excluded
RAPID-PsA [41] Certolizumab
200 mg§
Certolizumab
400 mg§
Placebo
No Yes Up to 40% of patients included were
permitted to have received one or more
anti-TNF agent previously, with a washout
period of 3 months before baseline visit
(28 days for etanercept)
Patients who had had previous
exposure to 2 biologics or 1
anti-TNF agent for the treatment
of PsA or psoriasis, or primary
failure of a previous anti-TNF
agent, defined as no response
within the first 12 weeks of
treatment, were excluded
Schett et al. [42] Apremilast 20 mg
Apremilast 40 mg
Placebo
Study publication did not differentiate
between primary and secondary
treatment failure
Patients were permitted to have received
previous biologic therapy, with a washout
period of ≥ 56 days for etanercept and ≥
84 days for adalimumab or infliximab
NA
†Primary treatment failure was defined as non-response to treatment.
‡Secondary treatment failure was defined as loss of response to treatment over time.
§With a 400 mg loading dose.
Bold text indicates studies that were included in the biologic-experienced network for American College of Rheumatology responses.
BIW: Twice per week; NA: Not applicable; PsA: Psoriatic arthritis.
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CZP 400 mg†
CZP 200 mg† SEC 150 mg
SEC 300 mg
APR 20 mg
APR 30 mg
GOL 50 mg
GOL 100 mg
UST 45 mg
UST 90 mg
ADA 40 mg
INF 5 mg/kg
GO-REVEAL
GO-REVEAL
GO-REVEAL
RAPID-PsA
RAPID-PsA
RAPID-PsA
FUTURE 2 FUTURE 2
FUTURE 2ADEPT
IMPACT
IMPACT2
PALACE 1
PALACE 2
PALACE 3
PALACE 1
PALACE 2
PALACE 3
PALACE 1
PALACE 2
PALACE 3
PSUMMIT1
PSUMMIT2
PSUMMIT1
PSUMMIT2
PSUMMIT1
PSUMMIT2
Placebo
CZP 400 mg†
CZP 200 mg† SEC 150 mg
SEC 300 mg
APR 30 mg
APR 20 mg
ETN 25 mg BIW
ETN 50 mg QW
ETN 50 mg BIW
GOL 100 mg
GOL 50 mg
UST 45/90 mg‡
ADA 40 mg
INF 5 mg/kg
GO-REVEAL
GO-REVEAL
GO-REVEAL
ADEPT
SPIRIT-P1
IMPACT
IMPACT2
PALACE 1
PALACE 2
PALACE 3
PALACE 1
PALACE 2
PALACE 3
PALACE 1
PALACE2
PALACE 3
RAPID-PsA
ERASURE
FIXTURE
FUTURE 2
ERASURE
FIXTURE
FUTURE 2
ERASURE
FIXTURE
FUTURE 2
RAPID-PsA
RAPID-PsA
FIXTURE
FIXTURE
FIXTURE
PRESTA
Mease et al. (2000)
Placebo
CLEAR
SEC 300 mg
SEC 150 mg
APR 20 mg
APR 40 mg
ADA 40 mg
INF 5 mg/kg
APR 30 mg
ETN 25 mg BIW
GOL 50 mg
GOL 100 mg
GO-REVEAL
GO-REVEAL
GO-REVEAL
IMPACT
IMPACT2
PALACE 1
PALACE 2
PALACE 3
PALACE 1
PALACE 2
PALACE 3
PALACE 1
PALACE 2
PALACE 3
CZP 200 mg†
CZP 400 mg†
RAPID-PsA
RAPID-PsA
RAPID-PsA
FUTURE 2 FUTURE 2
FUTURE 2
Placebo
ADEPT
Genovese et al. (2007)
Mease et al. 
(2000)
Schett et al. (2012)
Schett et al. (2012)
Schett et al. (2012)
Mease et al. 
(2004)
Figure 1. Treatment networks for the mixed populations of patients with PsA. (A) ACR responses at 16 weeks, (B) PASI responses at
12–16 weeks and (C) PsARC responses at 12–16 weeks. Populations containing biologic-naive and biologic-experienced patients:
apremilast, certolizumab, etanercept (for PASI data; population composition for PsARC data not reported), secukinumab, ustekinumab.
Populations containing biologic-naive patients only: adalimumab, golimumab, infliximab.
†With a 400 mg loading dose.
‡Patients received ustekinumab 45 or 90 mg in the CLEAR trial, depending upon bodyweight; therefore, patients receiving either dose
were treated as a single treatment group.
ACR: American College of Rheumatology; ADA: Adalimumab; APR: Apremilast; BIW: Twice per week; CZP: Certolizumab; ETN: Etanercept;
GOL: Golimumab; INF: Infliximab; PASI: Psoriasis Area Severity Index; PsARC: Psoriatic Arthritis Response Criteria; QW: Once weekly; SEC:
Secukinumab; UST: Ustekinumab.
smaller sizes of the biologic-naive and biologic-experienced patient populations meant that use of a random-effects
model was not feasible, because there were either insufficient degrees of freedom to conduct the analysis or so few
degrees of freedom that the posterior distribution of the between-study heterogeneity remained large, leading to
nonsensical, posterior distributions for the efficacy parameters. Therefore, fixed-effects models were used in these
populations.
ACR networks (16 weeks)
Mixed population
In the mixed population, the treatment network permitted comparisons for all therapies, with the exception of
etanercept (Figure 1A). Populations for adalimumab, golimumab and infliximab were biologic-naive, whereas those
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for other therapies were mixed. For all treatments, there was statistical evidence of superior ACR20 response rates
at 16 weeks, compared with placebo. Secukinumab 150 and 300 mg both demonstrated statistical superiority over
apremilast 20 or 30 mg and ustekinumab 45 mg (Figure 2A & B). Furthermore, infliximab 5 mg/kg, golimumab
50 and 100 mg and adalimumab 40 mg demonstrated statistical superiority in terms of ACR20 response rates over
apremilast 20 or 30 mg and ustekinumab 45 or 90 mg (Supplementary Table 2). These treatments were associated
with similar or slightly higher response rates when compared with secukinumab, but without statistical evidence of
superiority. ACR50 and ACR70 responses showed similar trends to ACR20 (Supplementary Tables 3 & 4).
Biologic-naive subpopulation
Eight trials were included in the treatment network for this subpopulation. In terms of ACR20, ACR50 and ACR70
response rates, all treatments demonstrated superiority over placebo. Adalimumab and secukinumab 150 mg
demonstrated superiority over both doses of apremilast and both doses of ustekinumab. Secukinumab 300 mg
demonstrated statistical superiority over apremilast 20 mg and ustekinumab 45 mg only; pairwise comparisons
against apremilast 30 mg (RR [95% CI]: 1.62 [1.00–2.60]) and ustekinumab 90 mg (RR [95% CI]: 1.44 [0.96–
2.07]) fell just short of statistical superiority in favor of secukinumab 300 mg (Figure 2C & D; Supplementary
Tables 5–7). Infliximab and both doses of golimumab demonstrated statistical superiority over all treatments in the
network, with the exception of adalimumab and secukinumab.
Biologic-experienced subpopulation
The NMA for ACR responses in the biologic-experienced population included four trials (see Table 2 for patient
inclusion criteria). All treatments except ustekinumab 45 and 90 mg showed evidence of superiority to placebo.
No therapy demonstrated statistical superiority over other treatments, except for certolizumab (200 and 400 mg
doses considered as a single treatment group), which showed statistical superiority over either dose of ustekinumab
(Supplementary Figure 3; Supplementary Tables 8–10).
PASI networks (12–16 weeks)
Mixed population
The treatment network for the mixed population allowed comparisons between all therapies included in this study
(Figure 1B). In CLEAR, patients received ustekinumab 45 or 90 mg, depending upon bodyweight, in line with
the licensed dosing scheme [9,45]; the doses were considered as a single treatment group for this analysis. Patient
populations for adalimumab, golimumab and infliximab were biologic-naive; populations for all other therapies
were mixed.
In terms of response rates for PASI50, PASI75 and PASI90, all treatments demonstrated superiority over placebo.
Secukinumab 150 or 300mg demonstrated statistical superiority to apremilast 20 and 30mg, certolizumab 200 and
400 mg, adalimumab 40 mg and etanercept 25 and 50 mg twice per week and 50 mg weekly. Furthermore, there
was evidence of superiority for secukinumab 300 mg compared with golimumab 50 mg (Figure 3; Supplementary
Tables 11–13). Similarly, infliximab demonstrated statistical superiority to all treatments apart from secukinumab,
golimumab 100 mg and ustekinumab 45/90 mg. Infliximab was associated with slightly higher response rates than
secukinumab, but without evidence of statistical superiority.
Biologic-naive subpopulation
The treatment network for the biologic-naive population included only five trials, and compared secukinumab
150 and 300 mg with adalimumab 40 mg, golimumab 50 and 100 mg and infliximab 5 mg/kg. All treatments
demonstrated superiority over placebo in terms of PASI50, PASI75 and PASI90 responses. There was statistical
evidence of superiority for infliximab over golimumab 50 mg and adalimumab 40 mg, and for golimumab 100 mg
over golimumab 50 mg. All analyses marginally favored either dose of secukinumab over golimumab 50 mg or
adalimumab 40 mg; however, none of these pairwise comparisons demonstrated evidence of statistical superiority
(Supplementary Figure 4; Supplementary Tables 14–16).
PsARC responses (12–16 weeks)
Mixed population
The treatment network for PsARC in the mixed population included all therapies in this study except ustekinumab
(Figure 1C). As in the other networks, patient populations were biologic-naive for some treatments and mixed for
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UST 90 mg
UST 45 mg
INF 5 mg/kg
GOL 100 mg
GOL 50 mg
CZP 400 mg†
CZP 200 mg†
APR 30 mg
APR 20 mg
ADA 40 mg
Placebo
1.57
1.88
0.78
0.82
0.82
1.34
1.27
1.78
1.94
0.98
3.47
(0.95–2.53)
(1.10–3.07)
(0.50–1.09)
(0.52–1.25)
(0.51–1.25)
(0.79–2.37)
(0.75–2.19)
(1.11–2.69)
(1.19–2.93)
(0.62–1.53)
(2.28–4.70)
Favors comparator Favors secukinumab 150 mg ACR20 – mixed population
5.04.54.03.53.02.52.01.51.00.50.0
Relative risk
UST 90 mg
UST 45 mg
INF 5 mg/kg
GOL 100 mg
GOL 50 mg
CZP 400 mg†
CZP 200 mg†
APR 30 mg
APR 20 mg
ADA 40 mg
Placebo
1.51
1.80
0.74
0.78
0.78
1.28
1.21
1.71
1.84
0.93
3.31
(0.89–2.44)
(1.02–2.96)
(0.46–1.06)
(0.47–1.21)
(0.48–1.20)
(0.74–2.28)
(0.69–2.11)
(1.03–2.63)
(1.12–2.87)
(0.57–1.48)
(2.12–4.59)
Favors comparator Favors secukinumab 300 mg ACR20 – mixed population
5.04.54.03.53.02.52.01.51.00.50.0
Relative risk
UST 90 mg
UST 45 mg
INF 5 mg/kg
GOL 100 mg
GOL 50 mg
CZP 200/400 mg‡
APR 30 mg
APR 20 mg
ADA 40 mg
Placebo
1.52
1.95
0.90
0.87
0.87
1.34
1.72
2.51
1.04
3.45
(1.03–2.16)
(1.29–2.86)
(0.63–1.27)
(0.60–1.20)
(0.60–1.20)
(0.90–1.92)
(1.09–2.71)
(1.52–4.29)
(0.72–1.43)
(2.42–4.53)
Favors comparator Favors secukinumab 150 mg ACR20 – biologic-naïve population
5.04.54.03.53.02.52.01.51.00.50.0
Relative risk
UST 90 mg
UST 45 mg
INF 5 mg/kg
GOL 100 mg
GOL 50 mg
CZP 200/400 mg‡
APR 30 mg
APR 20 mg
ADA 40 mg
Placebo
1.44
1.84
0.86
0.82
0.83
1.27
1.62
2.37
0.99
3.26
(0.96–2.07)
(1.21–2.74)
(0.58–1.22)
(0.57–1.15)
(0.56–1.15)
(0.84–1.85)
(1.00–2.60)
(1.39–4.12)
(0.67–1.37)
(2.25–4.37)
Favors comparator Favors secukinumab 300 mg ACR20 – biologic-naïve population
5.04.54.03.53.02.52.01.51.00.50.0
Relative risk
Figure 2. Relative risks of achieving an ACR20 response at 16 weeks. (A) Secukinumab 150 mg in the mixed population; (B)
secukinumab 300 mg in the mixed population; (C) secukinumab 150 mg in the biologic-naive population; and (D) secukinumab 300 mg in
the biologic-naive population.
Data shown are the estimated comparative effect (relative risk [and 95% credible interval, which can be interpreted as a confidence
interval]) of secukinumab versus the treatments indicated in the left-hand column. Values in bold text indicate comparisons with evidence
of superiority for secukinumab. Populations containing biologic-naive and biologic-experienced patients: apremilast, certolizumab,
secukinumab, ustekinumab. Populations containing biologic-naive patients only: adalimumab, golimumab, infliximab.
†With a 400 mg loading dose.
‡Results for both doses of CZP (200 and 400 mg) were combined in the biologic-naive subpopulation.
ACR20: At least a 20% improvement in the core set of American College of Rheumatology measures for assessing arthritis; ADA:
Adalimumab; APR: Apremilast; CZP: Certolizumab; GOL: Golimumab; INF: Infliximab; UST: Ustekinumab.
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28.00.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.0 22.0 24.0 26.0
Favors comparator Favors secukinumab 150 mg PASI75 – mixed population
Relative risk
UST 45/90 mg†
INF 5 mg/kg
GOL 100 mg
GOL 50 mg
ETN 50 mg QW
ETN 50 mg BIW
ETN 25 mg BIW
CZP 400 mg‡
CZP 200 mg‡
APR 30 mg
APR 20 mg
ADA 40 mg
Placebo
1.24
0.86
1.18
1.59
2.78
1.60
4.26
3.05
2.67
3.99
5.89
1.62
16.74
(0.83–2.37)
(0.62–1.22)
(0.78–1.99)
(0.96–2.98)
(1.41–7.08)
(1.06–2.87)
(1.49–16.99)
(1.61–6.64)
(1.47–5.55)
(2.39–6.91)
(3.34–10.71)
(1.03–2.76)
(11.20–24.44)
28.00.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.0 22.0 24.0 26.0
Favors comparator Favors secukinumab 300 mg PASI75 – mixed population
Relative risk
UST 45/90 mg†
INF 5 mg/kg
GOL 100 mg
GOL 50 mg
ETN 50 mg QW
ETN 50 mg BIW
ETN 25 mg BIW
CZP 400 mg‡
CZP 200 mg‡
APR 30 mg
APR 20 mg
ADA 40 mg
Placebo
1.36
0.94
1.29
1.72
3.03
1.75
4.63
3.34
2.91
4.37
6.41
1.77
18.25
(0.96–2.48)
(0.69–1.29)
(0.87–2.14)
(1.06–3.24)
(1.54–7.76)
(1.16–3.18)
(1.70–18.33)
(1.78–7.15)
(1.61–5.94)
(2.65–7.44)
(3.70–11.59)
(1.17–2.96)
(12.61–26.22)
Figure 3. Relative risks of achieving at least a 75% reduction in Psoriasis Area Severity Index score responses at 12–16 weeks in the
mixed population (SPIRIT-P1 trial [23,24] included). Data shown are the estimated comparative effect (relative risk [and 95% credible
interval, which can be interpreted as a CI]) of secukinumab versus the treatment indicated in the left-hand column. Values in bold text
indicate comparisons with evidence of superiority for secukinumab. Populations containing biologic-naive and biologic-experienced
patients: apremilast, certolizumab, secukinumab, ustekinumab. Populations containing biologic-naive patients only: adalimumab,
golimumab, infliximab.
†Patients received ustekinumab 45 or 90 mg in the CLEAR trial, depending upon bodyweight; therefore, patients receiving either dose
were treated as a single treatment group.
‡With a 400 mg loading dose.
ADA: Adalimumab; APR: Apremilast; BIW: Twice per week; CZP: Certolizumab; ETN: Etanercept; GOL: Golimumab; INF: Infliximab; PASI75:
At least a 75% reduction in Psoriasis Area Severity Index score; QW: Once weekly; UST: Ustekinumab.
others, including secukinumab. Data for etanercept in this analysis were derived from the studies [32,33], which
did not report whether included patients had received previous biologic therapy. All treatments demonstrated
superiority to placebo. Etanercept 25 mg twice per week and infliximab were associated with statistical superiority
over adalimumab, and apremilast 20, 30 and 40mg. Certolizumab 200mg and secukinumab 150mg demonstrated
superiority to all doses of apremilast, whereas certolizumab 400 mg and secukinumab 300 mg were superior only to
apremilast 20 and 30 mg. Golimumab 100 mg was superior to apremilast 20 and 40 mg (Figure 4; Supplementary
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5.00.0 1.0 2.0 3.0 4.0
Favors comparator Favors secukinumab 150 mg PsARC – mixed population
Relative risk
INF 5 mg/kg
GOL 100 mg
GOL 50 mg
ETN 25 mg BIW
CZP 400 mg†
CZP 200 mg†
APR 40 mg
APR 30 mg
APR 20 mg
ADA 40 mg
Placebo
1.06
1.15
1.20
1.05
1.07
1.05
1.90
1.53
1.84
1.38
2.86
(0.71–1.43)
(0.72–1.85)
(0.72–2.66)
(0.73–1.34)
(0.85–1.39)
(0.80–1.30)
(1.06–4.51)
(1.11–2.02)
(1.27–2.41)
(0.90–1.99)
(1.98–3.40)
5.00.0 1.0 2.0 3.0 4.0
Favors comparator Favors secukinumab 300 mg PsARC – mixed population
Relative risk
INF 5 mg/kg
GOL 100 mg
GOL 50 mg
ETN 25 mg BIW
CZP 400 mg†
CZP 200 mg†
APR 40 mg
APR 30 mg
APR 20 mg
ADA 40 mg
Placebo
1.10
1.19
1.24
1.08
1.10
1.09
1.96
1.58
1.90
1.43
2.97
(0.65–1.49)
(0.66–1.94)
(0.66–2.79)
(0.67–1.40)
(0.83–1.41)
(0.76–1.34)
(0.99–4.72)
(1.03–2.10)
(1.18–2.51)
(0.82–2.07)
(1.83–3.54)
Figure 4. Relative risks of achieving Psoriatic Arthritis Response Criteria responses at 12–16 weeks in the mixed population. Data shown
are the estimated comparative effect (relative risk [and 95% credible interval, which can be interpreted as a confidence interval]) of
secukinumab versus the treatment indicated in the left-hand column. Values in bold text indicate comparisons with evidence of
superiority for secukinumab. Populations containing biologic-naive and biologic-experienced patients: apremilast, certolizumab,
secukinumab. Populations containing biologic-naive patients only: adalimumab, golimumab, infliximab. Population composition for
etanercept not reported.
†With a 400 mg loading dose.
ADA: Adalimumab; APR: Apremilast; BIW: Twice per week; CZP: Certolizumab; ETN: Etanercept; GOL: Golimumab; INF: Infliximab; PsARC:
Psoriatic Arthritis Response Criteria.
Table 17).
Biologic-naive subpopulation
The treatment network for PsARC in the biologic-naive population included only six trials and compared five
treatments. Adalimumab 40 mg, etanercept 25 mg twice per week and infliximab 5 mg/kg demonstrated statistical
superiority over placebo. Infliximab 5 mg/kg, golimumab 50 and 100 mg and etanercept 25 mg twice per week
were all associated with slightly higher response rates than secukinumab 150 and 300 mg; adalimumab 40 mg was
associated with slightly higher response rates than secukinumab 300 mg only. There was, however, no statistical
evidence of superiority for any treatment over an active comparator (Supplementary Figure 5; Supplementary Table
18).
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Discussion
This study used NMA to assess the relative efficacy of secukinumab and all other non-cDMARD PsA therapies
(biologics and tsDMARDs) approved at the time the analysis was conducted, with placebo as the common
comparator arm. Both articular and dermatologic manifestations of disease were examined in the analyses, via the
inclusion of ACR and PASI responses, respectively. An analysis of PsARC responses was also included. Although
this composite measure is included more frequently as a secondary endpoint in RCTs, rather than a primary
endpoint [46], it has been included in several health technology assessment submissions for biologic therapies for
the treatment of PsA. A recent NICE assessment recommended adjustment for placebo response when modeling
PsARC outcomes, which is reflected in the approach adopted in our analysis [47].
Disparities in inclusion criteria and patient recruitment between studies meant that ‘mixed’ networks contained
some patient populations that were biologic-naive, whereas patients in other trial populations were permitted to
have received one or several previous biologic therapies. Data for adalimumab, golimumab and infliximab were
derived exclusively from biologic-naive populations, whereas patients receiving apremilast, certolizumab, etanercept,
secukinumab or ustekinumab could have experienced previous failure of a biologic treatment.
In the mixed population, secukinumab, infliximab, golimumab and adalimumab demonstrated good efficacy in
terms of ACR20, ACR50 and ACR90 responses, in some cases showing statistical superiority over comparators.
Similarly, for PASI50, PASI75 and PASI90 responses, both doses of secukinumab and infliximab demonstrated
superiority over most other treatments in the analysis. The analysis assessing PsARC outcomes in the mixed
population favored infliximab and etanercept at dosages of 25 mg twice per week. Most treatments included in this
analysis demonstrated statistical superiority to some or all of the included doses of apremilast.
When treatment effects in biologic-naive patients were assessed separately, trends were similar to those in
the analyses of mixed populations for ACR outcomes, but differed slightly for PASI and PsARC outcomes; in
particular, fewer pairwise comparisons showed statistical superiority for a treatment over an active comparator in
these analyses. This may be due to the comparatively smaller evidence base for the biologic-naive networks, which
used data from 8, 5 and 6 trials for ACR, PASI and PsARC outcomes, respectively, in some cases using data
only from a subset of the included patients. In contrast, the networks for the mixed populations used data from
11, 15 and 13 full trial populations, respectively. Therefore, the statistical power of the analysis for biologic-naive
populations is likely to have been lower. This lack of statistical power may explain the fact that, in the biologic-naive
population, secukinumab 150 mg demonstrated statistical superiority to both doses of apremilast and both doses
of ustekinumab, whereas secukinumab 300 mg was superior to apremilast 20 mg and ustekinumab 45 mg, but
fell short of statistical superiority to apremilast 30 mg and ustekinumab 90 mg. Differences in dose response,
for example, a smaller difference in response between the two doses of secukinumab relative to apremilast or
ustekinumab, may also have had an impact upon this analysis.
ACR outcomes only were assessed in the biologic-experienced population. At present, no ACR efficacy data from
RCTs are available for adalimumab, etanercept, golimumab or infliximab in biologic-experienced populations; thus,
the analysis was limited to apremilast, certolizumab, secukinumab and ustekinumab. Certolizumab 200/400 mg
demonstrated superiority over either dose of ustekinumab, but there was no other evidence of statistical superiority.
It is likely that bias was introduced into the mixed- and biologic-experienced networks by disparities in inclusion
criteria across trials of PsA treatments (Table 2). For example, patients entering the RAPID-PsA trial for certolizumab
were permitted to have received no more than one previous anti-TNF treatment [41] and were excluded if they had
experienced primary failure of an anti-TNF therapy, which was defined as no response within the first 12 weeks
of treatment. In contrast, the FUTURE 2 trial for secukinumab permitted inclusion of patients with primary
or secondary treatment failure, and patients who had previously received up to three anti-TNF treatments could
be included in the study [27]. These differences meant that patients receiving secukinumab may have been more
difficult to treat than those receiving apremilast or certolizumab. In addition, the relatively small numbers of
patients in the overall study populations who had received previous biologic therapy meant that analyses using the
biologic-experienced networks had limited statistical power and, consequently, their results should be interpreted
with caution. Restriction of networks by time point also limited patient numbers in some cases; in the ACR
network, restriction of trials to those reporting week 16 data meant that a number of studies were not included.
NMA, when not adjusted using meta-regression, is not able to adjust for differences in study designs or patients’
baseline characteristics that are effect modifiers. In this analysis, patient populations are likely to have differed
in terms of background exposure to methotrexate or corticosteroids, disease activity, and baseline PASI scores.
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Consequently, heterogeneity across trials was a general limitation of this analysis, although several meta-regression
models were fitted where possible (see Supplementary Methods). Meta-regression adjustment for differences in
patient populations was not possible, because many of the trials in the analysis did not include biologic-experienced
patients. This disparity was addressed by the development of different networks depending on patients’ previous
treatment use. In biologic-naive networks, however, this introduced bias against treatments for which only a subset
of trial data could be used; despite the predefined sub-analyses for biologic-naive patients in these trials, they lack the
statistical power of trials containing exclusively biologic-naive patients. Some of the trials included in the networks,
such as SPIRIT-P1, were not powered for noninferiority comparisons or, in the case of the CLEAR, ERASURE
and FIXTURE trials, were designed to assess treatment effects in psoriasis, not PsA.
Overall, nine trials used NRI exclusively to account for missing data, whereas eight trials (for apremilast,
etanercept, golimumab, infliximab and ustekinumab) used last observation carried forward (Table 1), which can
bias analyses in favor of active treatment. Therefore, the NMA results may be biased against treatments for which
the more conservative NRI method had been employed. For PASI and PsARC outcomes, the combination of 12-
and 16-week time points may have introduced additional variation, biasing the analyses in favor of treatments for
which 16-week data were used.
The short 12–16-week timeframe is a limitation of this analysis, imposed by the need to make comparisons
only within the placebo-controlled phase of the trials. Although rapid treatment response is important following
treatment initialization, long-term sustained control of disease is the major aim of PsA therapy due to the chronic
nature of the condition [2]. For chronic conditions, meaningful treatment benefits, particularly in terms of quality of
life and social functioning, are most likely to be detected in the long term. Furthermore, for some treatments, such
as apremilast, maximum efficacy may not be reached until after the 12–16-week timeframe, meaning that treatment
effect may not be captured by a short-term analysis. Therefore, treatment comparisons with a longer time horizon
are a vital means of informing therapeutic decisions. This could be addressed by the use of an alternative method for
generating comparative data, such as matching-adjusted indirect comparison (MAIC). AlthoughMAIC can be used
to compare only two treatments at the same time, whereas NMA allows for multiple pairwise comparisons, MAIC
permits the included trials to be matched in terms of patient populations, disparities in imputation methods, and
study design or reporting differences. Furthermore, because a common comparator is not required, MAIC allows
the time horizon of analysis to be extended beyond the placebo-controlled phase. MAICs have been developed
examining secukinumab and relevant comparators [48,49].
Of the five published NMAs in PsA identified by the authors, three did not include secukinumab [16,17,20] and
the two that did include secukinumab had methodological limitations that impact the clinical relevance of the
results [18,19]. We therefore contend that the current NMA is the most robust analysis in PsA to date. The first NMA
to include secukinumab was published as a congress abstract in 2015, and compared all approved treatments using
data from 14 trials [18]. The results were similar to those of the current NMA, showing adalimumab, golimumab,
secukinumab (150 and 300mg), and infliximab to be associated with the lowest numbers needed to treat for ACR20
responses at week 24 in both the mixed and biologic-naive population. For PASI75 response at week 24 in the
mixed population, adalimumab, golimumab, secukinumab 300 mg and infliximab had lower numbers needed to
treat than the other treatments. However, this analysis did not account for the time at which patients switched from
placebo to active treatment, which was earlier than 24 weeks in most trials. This limits the validity of the results.
The second NMA to include secukinumab was published in 2016 and compared all PsA treatments approved at
the time of the study. This showed secukinumab to be associated with numerically greater ACR20 responses at
weeks 12–24 than apremilast, certolizumab and ustekinumab, although findings were not classically statistically
significant. However, the authors used pooled data for etanercept, infliximab, adalimumab and golimumab and
compared this grouping (older TNF inhibitors) against the newer therapies [19]. Thus, this study did not permit
pairwise comparisons between all individual treatments, and the validity of the results is compromised by this
limitation in the study design.
Conclusion
This NMA is methodologically sound and is the first NMA of all approved PsA therapies to date that accounts
for early placebo switching and permits for pairwise comparisons between all agents. This analysis found that
secukinumab 150 and 300 mg were superior to apremilast and demonstrated good efficacy across all outcomes;
furthermore, in the mixed population, both doses of secukinumab were superior to ustekinumab 45 mg in terms
of ACR outcomes, and superior to adalimumab, certolizumab and etanercept in terms of PASI outcomes. Of the
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other treatments examined, the anti-TNF agents infliximab and golimumab also demonstrated superiority to the
small-molecule inhibitor apremilast across ACR and PASI outcomes and PsARC responses.
As well as providing comparative evidence, indirect treatment comparisons can generate hypotheses that can be
tested in future RCTs. Head-to-head superiority trials in PsA, such as the ongoing trial EXCEED 1 [12], which
has been initiated to compare adalimumab and secukinumab, and SPIRIT-H2H [13], comparing adalimumab and
secukinumab, will be needed to provide directly comparative results.
Summary points
• Biologics and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) are recommended for the
treatment of active psoriatic arthritis (PsA) if conventional DMARDs employed as first-line therapies are not
successful.
• Given the limited number of head-to-head randomized, controlled trials comparing biologics and targeted
synthetic DMARDs for PsA, adjusted indirect comparisons, such as network meta-analysis, provide valuable
evidence differentiating between treatments.
• We conducted a systematic review to identify relevant trials for adalimumab, apremilast, certolizumab,
etanercept, golimumab, infliximab, secukinumab and ustekinumab.
• Separate networks were developed for full (mixed) study populations, for biologic-naive patients and for
biologic-experienced patients.
• In the mixed populations, secukinumab, adalimumab, golimumab and infliximab were associated with the
highest response rates according to American College of Rheumatology criteria at 16 weeks.
• Secukinumab and infliximab demonstrated the highest Psoriasis Area Severity Index response rates at
12–16 weeks in the mixed populations.
• Infliximab and etanercept demonstrated the highest Psoriatic Arthritis Response Criteria response rates at
12–16 weeks in the mixed populations.
• In this comprehensive network meta-analysis of licensed treatments for active PsA, secukinumab demonstrated
good efficacy across all outcomes examined in the mixed study populations.
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